AI Article Synopsis

  • Intestinal flora imbalances and butyrate metabolism issues occur before symptoms of rheumatoid arthritis (RA) and are linked to its development.
  • These issues can damage the intestinal barrier, allowing harmful substances to enter the bloodstream and worsen arthritis through inflammation.
  • Butyrate, an intestinal metabolite, plays a crucial role in regulating immune responses and protecting against joint damage, suggesting that improving butyrate production or supplementing it could be effective treatments for RA.

Article Abstract

In patients with rheumatoid arthritis (RA), intestinal flora imbalance and butyrate metabolism disorders precede clinical arthritis and are associated with the pathogenesis of RA. This imbalance can alter the immunology and intestinal permeability of the intestinal mucosa, leading to damage to the intestinal barrier. In this context, bacteria and their metabolites can enter the bloodstream and reach the distant target tissues of the host, resulting in local inflammation and aggravating arthritis. Additionally, arthritis is also exacerbated by bone destruction and immune tolerance due to disturbed differentiation of osteoclasts and adaptive immune cells. Of note, butyrate is a metabolite of intestinal flora, which not only locally inhibits intestinal immunity and targets zonulin and tight junction proteins to alleviate intestinal barrier-mediated arthritis but also inhibits osteoclasts and autoantibodies and balances the immune responses of T and B lymphocytes throughout the body to repress bone erosion and inflammation. Therefore, butyrate is a key intermediate linking intestinal flora to the host. As a result, restoring the butyrate-producing capacity of intestinal flora and using exogenous butyrate are potential therapeutic strategies for RA in the future.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521846PMC
http://dx.doi.org/10.3389/fimmu.2024.1475529DOI Listing

Publication Analysis

Top Keywords

intestinal flora
20
intestinal
10
rheumatoid arthritis
8
arthritis
6
butyrate
5
flora
5
butyrate bridge
4
bridge intestinal
4
flora rheumatoid
4
arthritis patients
4

Similar Publications

Severe acute pancreatitis (SAP) is one of the leading causes of hospital admissions for gastrointestinal diseases, with a rising incidence worldwide. Intestinal microbiota dysbiosis caused by SAP exacerbates systemic inflammatory response syndrome and organ dysfunction. Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic option for gastrointestinal diseases.

View Article and Find Full Text PDF

There is a complex interplay between the gut microbes, liver, and central nervous system, a gut-liver-brain axis, where the brain impacts intestinal and hepatic function while the gut and liver can impact cognition and mental status. Dysregulation of this axis can be seen in numerous diseases. Hepatic encephalopathy, a consequence of cirrhosis, is perhaps the best studied perturbation of this system.

View Article and Find Full Text PDF

High blood pressure is a significant risk factor for cardiovascular diseases and is linked to an increased risk of mild cognitive impairment (MCI). The lack of effective treatments for these conditions highlights the urgent need for novel therapeutic approaches. Recent research suggests that the gut microbiota-brain-gut axis plays a crucial role in the pathogenesis of hypertension and MCI by regulating the nervous, endocrine, and immune systems.

View Article and Find Full Text PDF

The circadian cycle is a fundamental biological rhythm that governs many physiological functions across nearly all living organisms. In the gastrointestinal tract, activities such as gut motility, hormone synthesis, and communication between the gut, central nervous system and microbiome all fluctuate in alignment with the circadian cycle. The enteric nervous system (ENS) is critical for co-ordinating many of these activities, however, how its activity is governed by the circadian cycle remains unknown.

View Article and Find Full Text PDF

L-Arginine-Modified Selenium Nanozymes Targeting M1 Macrophages for Oral Treatment of Ulcerative Colitis.

Small

January 2025

Department of Chemistry, Key Laboratory of Biomedical Functional Materials, School of Science, China Pharmaceutical University, Nanjing, 211198, P. R. China.

Ulcerative colitis (UC) involves persistent inflammation in the colon and rectum, with excessive reactive oxygen species (ROS) accumulation. This ROS buildup damages colonic epithelial cells and disrupts intestinal flora, worsening disease progression. Current antioxidant therapies are limited due to their instability in the gut and lack of targeting, hindering precise intervention at the lesion site.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!